Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 2/20 | 0.44 |
| ▸ | UGCG | Q16739 | 2/20 | 0.44 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.44 |
| ▸ | SPHK1 | Q9NYA1 | 13/20 | 0.41 |
| ▸ | SPHK2 | Q9NRA0 | 4/20 | 0.41 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1164544 | 0.91 | GBA1 (0.49) | GBA1UGCGGBA2SPHK1SPHK2 | |
| SCHEMBL30225094 | 0.91 | GBA1 (0.49) | GBA1UGCGGBA2SPHK1SPHK2 | |
| SCHEMBL4603376 | 0.90 | — | — | |
| SCHEMBL1164989 | 0.89 | GBA1 (0.51) | GBA1UGCGGBA2SPHK1SPHK2 | |
| SCHEMBL31601986 | 0.86 | GBA1 (0.44) | GBA1UGCGGBA2SPHK1SPHK2 | |
| SCHEMBL20109731 | 0.86 | MEN1 (0.39) | GBA1UGCGGBA2SPHK1SPHK2 | |
| SCHEMBL7536089 | 0.86 | GBA1 (0.44) | GBA1UGCGGBA2SPHK1SPHK2 | |
| SCHEMBL21215385 | 0.84 | MEN1 (0.50) | GBA1UGCGGBA2SPHK1SPHK2 | |
| SCHEMBL13096717 | 0.83 | TSHR (0.41) | GBA1UGCGGBA2SPHK1SPHK2 | |
| SCHEMBL4592512 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572592-B2 | Labelling compounds and their use in assays | BINX HEALTH LIMITED (GB) | 2023-02-07 | — | — | US | disclosed |
| US-20220025440-A1 | LABELLING COMPOUNDS AND THEIR USE IN ASSAYS | BINX HEALTH LIMITED (GB) | 2022-01-27 | — | — | US | disclosed |
| US-10968490-B2 | Labelling compounds and their use in assays | BINX HEALTH LIMITED (GB) | 2021-04-06 | — | — | US | disclosed |
| US-20180037937-A1 | Labelling Compounds and Their Use in Assays | KREOS CAPITAL VII (UK) LIMITED (GB) | 2018-02-08 | — | — | US | disclosed |
| EP-3055317-B1 | LABELLING COMPOUNDS AND THEIR USE IN ASSAYS | ATLAS GENETICS LTD (GB) | 2018-01-31 | — | — | EP | disclosed |
| US-9822398-B2 | Labelling compounds and their use in assays | ATLAS GENETICS LIMITED (GB) | 2017-11-21 | — | — | US | disclosed |
| WO-2015052516-A1 | LABELLING COMPOUNDS AND THEIR USE IN ASSAYS | ATLAS GENETICS LIMITED (GB) | 2015-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180037937-A1 | Labelling Compounds and Their Use in Assays | CYP2F1, CYP4F3, CYP4F2 | GBA1 366/4885UGCG 602/4885GBA2 733/4885 |
| US-20220025440-A1 | LABELLING COMPOUNDS AND THEIR USE IN ASSAYS | CYP2F1, CYP4F3, CYP4F2 | GBA1 366/4885UGCG 602/4885GBA2 733/4885 |
| US-11572592-B2 | Labelling compounds and their use in assays | CYP2F1, CYP4F3, CYP4F2 | GBA1 366/4885UGCG 602/4885GBA2 733/4885 |
| US-10968490-B2 | Labelling compounds and their use in assays | CYP2F1, CYP4F3, CYP4F2 | GBA1 366/4885UGCG 602/4885GBA2 733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.